MaxCyte, Inc. Appointment of Joint Corporate Broker (9190N)
February 03 2021 - 11:35AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 9190N
MaxCyte, Inc.
03 February 2021
MaxCyte, Inc.
("MaxCyte" or the "Company")
Appointment of Joint Corporate Broker
Gaithersburg, Maryland - 3 February 2021: MaxCyte (LSE: MXCT,
MXCL), a global cell-engineering and life sciences company,
announces the appointment of Stifel Nicolaus Europe Limited as the
Company's Joint Corporate Broker with immediate effect alongside
existing Joint Corporate Brokers Panmure Gordon and Numis.
MaxCyte +1 301 944 1660
Doug Doerfler, Chief Executive Officer
Amanda Murphy, Chief Financial Officer
Nominated Adviser and Joint Corporate Broker
Panmure Gordon (UK) Limited
Emma Earl / Freddy Crossley (Corporate Finance)
Rupert Dearden (Corporate Broking)
Joint Corporate Broker
Numis Securities Ltd.
James Black / Duncan Monteith / Matthew
O'Dowd +44 (0) 20 7886 2892
Joint Corporate Broker +44 (0) 20 7260 1000
Stifel Nicolaus Europe Limited
Nicholas Moore / Ben Maddison / Samira Essebiyea
(Healthcare Investment Banking)
Nick Adams (Corporate Broking) +44 (0) 20 7710 7600
Financial PR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott / Chris Welsh
About MaxCyte
MaxCyte is a world-leading provider of cell-engineering enabling
technology and is responsible for helping to bring next-generation
cell and gene-editing therapies to life. The Company's technology
is deployed by leading drug developers worldwide, including all of
the top ten global biopharmaceutical companies. MaxCyte licences
have been granted for more than 140 cell therapy programmes, with
more than 100 licensed for clinical use, and the Company has now
entered into twelve clinical/commercial license partnerships with
leading cell therapy and gene editing developers. MaxCyte was
founded in 1998, is listed on the London Stock Exchange (LSE: MXCT,
MXCL) and is headquartered in Gaithersburg, Maryland, US. For more
information, visit www.maxcyte.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
APPTJMFTMTBMBPB
(END) Dow Jones Newswires
February 03, 2021 11:35 ET (16:35 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024